Iomervu
(Iomeprol 350)ApprovedSmall molecule
Iomervu is one of 31 small molecule programs targeting Nephropathy. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
30
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Nephropathy
#DrugCompanyPhaseTrials
1Alka-Seltzer
AAbbott
Approved
Rocaltrol
Jazz PharmaceuticalsApproved
Theo-Dur
PfizerApproved
Rituxan
RocheApproved
Crestor
AstraZenecaApproved
Micardis
Boehringer IngelheimApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Nitrostat
VViatris Specialty LLC
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Zocor
OOrganon and Co
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Nov 27, 2024
IOMERVU
NDA NDA216016
Nov 27, 2024
IOMERVU
NDA NDA216017
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Iomeprol 350. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- BBracco Diagnostics, Inc